Denali Therapeutics Inc.
NASDAQ:DNLI · NASDAQ Global Select
+$0.09 today
Vol 2.52M · Avg 1.84M
Filings
Ground the analysis in primary documents
Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.
Price History
Dividend-adjusted closing price
Change
+71.15%
Period High
$23.49
Period Low
$12.75
Latest
$23.31
SEC Filings
Recent regulatory filings
No filings found.
Competitors
Peer companies in the same sector
ImmunityBio, Inc.
NASDAQ:IBRX
$7.39B
Liquidia Corporation
NASDAQ:LQDA
$6.10B
Cogent Biosciences, Inc.
NASDAQ:COGT
$5.93B
Beam Therapeutics Inc.
NASDAQ:BEAM
$3.42B
Arcus Biosciences, Inc.
NYSE:RCUS
$2.44B
89bio, Inc.
ETNB
$2.20B
Agios Pharmaceuticals, Inc.
NASDAQ:AGIO
$2.01B
Galapagos N.V.
GLPG
$1.84B
Viridian Therapeutics, Inc.
NASDAQ:VRDN
$1.51B
Recursion Pharmaceuticals, Inc.
NASDAQ:RXRX
$1.41B
What is the latest DNLI filing?
The latest filing shown is 8-K dated Jun 18, 2026.
How many recent filings does DNLI have?
Intrinsic Alpha currently shows 20 recent filings for DNLI.
Explore More
Continue the stock analysis
Jump to another research area for this company.